Stockscreener 앱 받기
320.39
5.75%
-19.54
시장 영업 전:
314.27
-6.12
-1.91%
전일 마감가:
$339.93
열려 있는:
$336.02
하루 거래량:
479.03K
Relative Volume:
1.04
시가총액:
$8.92B
수익:
$7.46M
순이익/손실:
$-303.27M
주가수익비율:
-23.79
EPS:
-13.4668
순현금흐름:
$-249.12M
1주 성능:
+0.05%
1개월 성능:
+5.05%
6개월 성능:
+96.91%
1년 성능:
+974.23%
1일 변동 폭
$314.14
$340.42
1주일 범위
$312.89
$352.78
52주 변동 폭
$29.47
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
320.39 | 9.47B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Strong Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-02 | 개시 | Wells Fargo | Equal Weight |
| 2025-12-15 | 재확인 | Oppenheimer | Outperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis Precision gains as lead asset accepted for FDA review - MSN
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1%Time to Sell? - MarketBeat
Why is Praxis Precision stock soaring Tuesday? - MSN
Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $437 - Moomoo
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $437 From $412, Maintains Buy Rating - marketscreener.com
PRAX Reiterated by Needham -- Price Target Maintained at $510 - GuruFocus
FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com Australia
Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks
FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance - Investing.com UK
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance By Investing.com - Investing.com India
Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review - Investing.com UK
Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com - Investing.com Australia
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Praxis Precision Medicines' (PRAX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application - marketscreener.com
Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027 - Quiver Quantitative
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor - Bitget
FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - National Today
7 million Americans with essential tremor see a first positive Phase 3 program - Stock Titan
Praxis Precision Medicines (NASDAQ:PRAX) Upgraded to Strong-Buy at Raymond James Financial - MarketBeat
Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target - marketscreener.com
Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy - Investing.com
A Look At Praxis Precision Medicines (PRAX) Valuation After Positive Elsunersen Seizure Reduction Data - simplywall.st
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
PRAX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Wolfe Research Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $500 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $500 to $1,245 - Moomoo
Praxis Adds To Neuroscience Momentum With Epilepsy Trial Success - Citeline News & Insights
H.C. Wainwright reiterates Praxis Precision stock rating on trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Praxis Precision stock rating on trial data - Investing.com
HC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRAX with $1245 Ta - GuruFocus
Praxis Precision Medicines Announces Positive EMBRAVE Part A Trial Results for Elsunersen in Pediatric SCN2A Epileptic Encephalopathy - Minichart
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine - Investing.com Australia
Praxis reports positive elsunersen trial in pediatric epilepsies - TipRanks
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine By Investing.com - Investing.com South Africa
Praxis Precision reports positive Phase 1/2 elsunersen results; FDA sets PDUFA for relutrigine - TradingView — Track All Markets
Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine - Stock Titan
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX) - Seeking Alpha
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PR - GuruFocus
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PRAX Stock News - gurufocus.com
BTIG Research Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - marketbeat.com
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
0.77%
자본화:
|
볼륨(24시간):